JP2022520061A5 - - Google Patents

Info

Publication number
JP2022520061A5
JP2022520061A5 JP2021546264A JP2021546264A JP2022520061A5 JP 2022520061 A5 JP2022520061 A5 JP 2022520061A5 JP 2021546264 A JP2021546264 A JP 2021546264A JP 2021546264 A JP2021546264 A JP 2021546264A JP 2022520061 A5 JP2022520061 A5 JP 2022520061A5
Authority
JP
Japan
Prior art keywords
independently
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021546264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017364 external-priority patent/WO2020163823A2/en
Publication of JP2022520061A publication Critical patent/JP2022520061A/ja
Publication of JP2022520061A5 publication Critical patent/JP2022520061A5/ja
Pending legal-status Critical Current

Links

JP2021546264A 2019-02-08 2020-02-07 治療薬および治療方法 Pending JP2022520061A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962803299P 2019-02-08 2019-02-08
US62/803,299 2019-02-08
PCT/US2020/017364 WO2020163823A2 (en) 2019-02-08 2020-02-07 Therapeutic agents and methods of treatment

Publications (2)

Publication Number Publication Date
JP2022520061A JP2022520061A (ja) 2022-03-28
JP2022520061A5 true JP2022520061A5 (cg-RX-API-DMAC7.html) 2023-05-23

Family

ID=71948254

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546264A Pending JP2022520061A (ja) 2019-02-08 2020-02-07 治療薬および治療方法

Country Status (8)

Country Link
US (1) US20220169628A1 (cg-RX-API-DMAC7.html)
EP (1) EP3920923A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022520061A (cg-RX-API-DMAC7.html)
KR (1) KR20210137025A (cg-RX-API-DMAC7.html)
CN (1) CN113660937A (cg-RX-API-DMAC7.html)
AU (1) AU2020218367A1 (cg-RX-API-DMAC7.html)
CA (1) CA3127501A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020163823A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3163593A1 (en) * 2020-01-15 2021-07-22 Guangrong Zheng Therapeutic agents and methods of treatment
US12673106B2 (en) 2020-08-28 2026-07-07 University Of Florida Research Foundation, Incorporated Modulators of nuclear receptor subfamily 4 group A member 1 (NR4A1) and uses thereof
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的bcl-xl protac化合物及び使用の方法
US20240408085A1 (en) * 2021-09-01 2024-12-12 Xizang Haisco Pharmaceutical Co., Ltd. Compound for degradation of bcl-2 family proteins and medical application thereof
US20240398764A1 (en) * 2021-10-12 2024-12-05 University Of Florida Research Foundation, Incorporated Methods of treating diseases associated with senescent cell accumulation
CN118660886A (zh) 2021-12-09 2024-09-17 佛罗里达大学研究基金公司 用于治疗癌症的bcl-xl/bcl-2双重降解剂
CA3240051A1 (en) 2021-12-30 2023-07-06 Beigene Switzerland Gmbh Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN116396288B (zh) * 2022-01-04 2026-04-03 上海科技大学 基于bcl-2家族蛋白配体化合物开发的蛋白降解剂及它们的应用
AU2023264537A1 (en) 2022-05-06 2024-11-14 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
PE20250007A1 (es) 2022-05-06 2025-01-07 Treeline Biosciences Inc Degradadores bcl-xl-heterobifuncionales de tetrahidroisoquinolina
EP4519260A1 (en) 2022-05-06 2025-03-12 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xdegraders
US20260092057A1 (en) * 2022-05-12 2026-04-02 Kymera Therapeutics, Inc. Bcl-xl/bcl-2 degraders and uses thereof
CN115028679B (zh) * 2022-08-11 2022-11-15 深圳湾实验室 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用
CN120659777A (zh) * 2022-10-03 2025-09-16 佛罗里达大学研究基金公司 募集Cereblon的Bcl-xL/Bcl-2双重降解剂
WO2024078581A1 (en) * 2022-10-12 2024-04-18 Appicine Therapeutics (Hk) Limited Selective bcl-xl protac compounds and uses thereof
CN120569222A (zh) * 2023-01-18 2025-08-29 苏州宜联生物医药有限公司 包含bcl-2家族蛋白降解剂的抗体药物偶联物及其制备方法和用途
CN121652220A (zh) * 2023-02-17 2026-03-13 正大天晴药业集团股份有限公司 含有三氟甲磺酰基的化合物
AU2024378690A1 (en) 2023-11-07 2026-05-07 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
IL327973A (en) 2023-11-07 2026-06-01 Treeline Biosciences Inc Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
KR20260111020A (ko) 2023-11-07 2026-07-14 트리라인 바이오사이언시스, 인크. 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제
WO2026015489A1 (en) * 2024-07-08 2026-01-15 University Of Florida Research Foundation, Incorporated Bcl-xl/bcl-2 dual degraders and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
AU2016232705C1 (en) * 2015-03-18 2021-06-17 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2017024317A2 (en) * 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CA3045037A1 (en) * 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
US20240398764A1 (en) * 2021-10-12 2024-12-05 University Of Florida Research Foundation, Incorporated Methods of treating diseases associated with senescent cell accumulation
CN118660886A (zh) * 2021-12-09 2024-09-17 佛罗里达大学研究基金公司 用于治疗癌症的bcl-xl/bcl-2双重降解剂

Similar Documents

Publication Publication Date Title
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP2019517487A5 (cg-RX-API-DMAC7.html)
JP2018517686A5 (cg-RX-API-DMAC7.html)
JP2009536220A5 (cg-RX-API-DMAC7.html)
JP2011057693A5 (cg-RX-API-DMAC7.html)
JP2024054295A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
JP2006503850A5 (cg-RX-API-DMAC7.html)
JP2024546095A5 (cg-RX-API-DMAC7.html)
JP2007520452A5 (cg-RX-API-DMAC7.html)
CN110769837A (zh) 与五氮杂大环状环配合物的联合癌症免疫疗法
JP2015517523A5 (cg-RX-API-DMAC7.html)
JP2021534160A5 (cg-RX-API-DMAC7.html)
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
JPWO2021187548A5 (cg-RX-API-DMAC7.html)
KR20080004495A (ko) 암을 치료하기 위한 조합물, 방법 및 조성물
JP6422936B2 (ja) 5−ブロモ−インジルビン
JP2009536956A (ja) 抗癌治療法
JP2026071339A (ja) ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
US6355628B1 (en) Combination therapy using pentafluorobenzenesulfonamides
JP2022502378A5 (cg-RX-API-DMAC7.html)
JP2016503035A (ja) 肝疾患または肝障害の治療のための使用および方法
EP1757283B1 (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
WO2013137433A1 (ja) 3剤を組み合わせた新規な抗腫瘍剤
JP5409613B2 (ja) 抗腫瘍剤、キット及び癌治療方法
JP2019525924A5 (cg-RX-API-DMAC7.html)